ERBB2 and breast cancer: In addition to gene regulators, proliferative markers such as Ki67 and oncogenic drivers like HER2 have also been highlighted in nanotherapeutic evaluations of MoS2/VS2 nanocomposites, demonstrating promising cytotoxicity against breast cancer cells [127].